Prosecution Insights
Last updated: August 17, 2026
Application No. 18/674,715

SMALL MOLECULE INHIBITORS OF INTERLEUKIN-4

Non-Final OA §102
Filed
May 24, 2024
Priority
Mar 20, 2020 — provisional 62/992,434 +1 more
Examiner
RAHMANI, NILOOFAR
Art Unit
Tech Center
Assignee
Massachusetts Institute of Technology
OA Round
1 (Non-Final)
78%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
74%
With Interview

Examiner Intelligence

Grants 78% — above average
78%
Career Allowance Rate
882 granted / 1138 resolved
+17.5% vs TC avg
Minimal -3% lift
Without
With
+-3.1%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 11m
Avg Prosecution
40 currently pending
Career history
1152
Total Applications
across all art units

Statute-Specific Performance

§101
2.7%
-37.3% vs TC avg
§103
14.0%
-26.0% vs TC avg
§102
27.8%
-12.2% vs TC avg
§112
39.1%
-0.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1138 resolved cases

Office Action

§102
DETAILED ACTION Claims 28-47 are pending in the instant application. Applicant’s election of Group (III) in the reply filed on 07/13/2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). The requirement is still deemed proper and is therefore made FINAL. Claims 28-31, 33, 37-39, 44 in part wherein B1 is C; B2 is CRB2; RB2 is CN; B3 is CRB3; RB3 is NH2, halide, or SH; B4 is N; B5 is C; B6 is CRB; RB6 is alkyl or H; R2 is aryl substituent with Fluoro are examined. Claims 32, 34-36, 40-43, 45-47 and the remaining subject matter of claims 28-31, 33, 37-39, 44 are withdrawn per 37 CFR 1.142(b). 2. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 28-31, 33, 37-39, 44 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Kohler et al., Journal of the American Chemical Society (1922), 44, 2903-14. Kohler et al. discloses the instant claimed compound, which from the STN search is PNG media_image1.png 530 646 media_image1.png Greyscale , which anticipates the instant compounds. Therefore, the instant claims are anticipated by Kohler et al. 3. Claims 28-31, 33, 37-39, 44 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Prakash et al., Journal of Fluorine Chemistry (1988), 41(3), 303-10. Prakash et al. discloses the instant claimed compound, which from the STN search is PNG media_image2.png 278 718 media_image2.png Greyscale , which anticipates the instant compounds. Therefore, the instant claims are anticipated by Prakash et al. 4. Claims 28-31, 33, 37-39, 44 are rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by Yang et al., CN 102838536. Yang et al. discloses the instant claimed compound, which from the STN search is PNG media_image3.png 306 734 media_image3.png Greyscale , which anticipates the instant compounds. Therefore, the instant claims are anticipated by Yang et al. 5. Claims 28-31, 33, 37-39, 44 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Kurumurthy et al., Research on Chemical Intermediates (2015), 41(5), 3193-3199. Kurumurthy et al. discloses the instant claimed compound, which from the STN search is PNG media_image4.png 278 744 media_image4.png Greyscale , which anticipates the instant compounds. Therefore, the instant claims are anticipated by Kurumurthy et al. 6. Claims 28-31, 33, 37-39, 44 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Murumkar et al., Medicinal Chemistry Research (2015), 24(1), 226-244. Murumkar et al. discloses the instant claimed compound, which from the STN search is PNG media_image4.png 278 744 media_image4.png Greyscale , which anticipates the instant compounds. Therefore, the instant claims are anticipated by Murumkar et al. 7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Niloofar Rahmani whose telephone number is 571-272-4329. The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor, can be reached on 571-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /NILOOFAR RAHMANI/ 07/27/2026
Read full office action

Prosecution Timeline

May 24, 2024
Application Filed
Jul 13, 2026
Response after Non-Final Action
Jul 30, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12703700
GLP-1R Agonist and Therapeutic Method Thereof
1y 0m to grant Granted Aug 11, 2026
Patent 12696901
PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS
4y 1m to grant Granted Aug 04, 2026
Patent 12698270
ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS
3y 2m to grant Granted Aug 04, 2026
Patent 12686660
Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same
2y 5m to grant Granted Jul 21, 2026
Patent 12678444
SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER
2y 5m to grant Granted Jul 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
78%
Grant Probability
74%
With Interview (-3.1%)
1y 11m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1138 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month